These results suggested that PPD plus Zeb combination therapy could upregulate the levels of some CTA genes (SSX-9, MAGE-A3, SSX-b2, Taf7l, Ctcfl, and Lipa) accompanied by enhancement of MHC I (H2-Db and H2-Kb) and downregulate the PD-L1 expression in tumour tissue, resulting in an increase in immunoactivated cytokines and a decrease in immunosuppressive cytokines, all of which were beneficial to inhibit tumour growth. The gene discussed is SSX2; the disease is neoplasm.